Amin Sharifan, PharmD

Abdulazeem, H.; Borges do Nascimento, I.J.; Weerasekara, I.; Sharifan, A.; Grandi Bianco, V.; Cunningham, C.; Kularathne, I.; Deeken, G.; de Barros, J.; Sathian, B.; Østengaard, L.; Lamontagne-Godwin, F.; van Hoof, J.; Lazeri, L.; Redlich, C.; Marston, H.R.; Alistair Dos Santos, R.; Azzopardi-Muscat, N.; Yon, Y.; Novillo-Ortiz, D. (2025). Use of Digital Health Technologies for Dementia Care: Bibliometric Analysis and Report. JMIR Ment Health, 12:e64445: 10.2196/64445

Feigin, V. L. ; Vos, T.; Nair, B. S.; Hay, S. I.; Abate, Y. H.; Abd Al Magied, A. H. A.; et al. (2025). Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Public Health, 10: e203-27

GBD 2021 Europe Life Expectancy Collaborators; Steel, N., Sharifan, A. (2025). Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021. Lancet Public Health, 10: e172–88

GBD 2021 Global Subarachnoid Hemorrhage Risk Factors Collaborators (2025). Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage. The Global Burden of Disease Study 2021. JAMA Neurology, 10.1001/jamaneurol.2025.1522: E1-E23

GBD 2021 Suicide Collaborators; Davis Weaver, N.; Sharifan, A.; (2025). Global, regional, and national burden of suicide, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health, 10: e189-e202

Kerr, J. A.; Patton, G. C.; Cini, K. I.; Abate, Y. H.; Abbas, N.; Abd Al Magied, A. H. A.; et al. (2025). Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet, 405: 785-812

Li, S.; Zhang, L.; Wang, Y.; Xie, R.; Chen, W.; Soo Lee, M.; Amer, Y.S.; Sharifan, A.; Hussein, H.; Li, H. (2025). Development and validation a methodology model for traditional Chinese medicine good practice recommendation: an exploratory sequential mixed methods study. Frontiers in Pharmacology, 16:1501634: 10.3389/fphar.2025.1501634

M. Ng,; E. Gakidou,; J. Lo,; Y. H. Abate,; C. Abbafati,; N. Abbas,; et al. (2025). Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet, 405: 813-38

Oh, J.; Kim, S.; Kim, M. S.; Abate, Y. H.; Abd ElHafeez, S.; Abdelkader, A.; et al. (2025). Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Respiratory Medicine, 13, 5: 425-446

S. Lee, Y. Son, J. Hwang, M. S. Kim, J. I. Shin, N. J. Kassebaum, et al. (2025). Global, regional and national burden of dietary iron deficiency from 1990 to 2021: a Global Burden of Disease study. Nature Medicine, https://doi.org/10.1038/s41591-025-03624-8: https://doi.org/10.1038/s41591-025-03624-8

Sharifan, A. (2025). Natural Compounds against Mpox: Mapping Evidence and Identifying Gaps. Planta Med, 91: 271-273

Sharifan, A. (2025). Bridging knowledge gaps in phytotherapy for a neglected zoonotic disease: Rift valley fever. Biomedicine & Pharmacotherapy, 187: https://doi.org/10.1016/j.biopha.2025.118092

Sharifan, A. (2025). Oncolytic Virotherapy in Otorhinolaryngologic Neoplasms: A Scoping Review and Bibliometric Analysis. American Journal of Therapeutics, 10.1097/MJT.0000000000001876: 10.1097/MJT.0000000000001876

Sharifan, A.; Abdulazeem, H.; Meckawy, R.; Sonkoue Pianta, M.; Abdelwahab, M.M.; Halder, A.; Gust Duque, T.; (2025). Appraisal of World Health Organization guidelines for priority infectious diseases with potential to cause public health emergencies. Public Health, 240: 112-118

Sofi-Mahmudi, A.; Stojanova, J.; Vounzoulaki, E.; Tomlinson, E.; Pizarro, A.B.; Khademioore, S.; Ngeh, E.; Sharifan, A.; Mrema, L.E.; Britten-Jones, A.C.; Castiello de Obeso, S.; Welch, V.A.; Mbuagbaw, L.; Tugwell, P. (2025). Cochrane reviews’ authorship has become more gender-diverse but remains geographically concentrated: a meta-research study. Journal of Clinical Epidemiology, 181: https://doi.org/10.1016/j.jclinepi.2025.111719

Sharifan, A. (2025). For adults with cancer, what are the benefits and harms of resistance training (either during or after anticancer therapy)? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4547: https://doi.org/10.1002/cca.4547

Sharifan, A. (2025). What are the effects of interventions to improve healthcare professionals' reporting of adverse drug reactions and medication errors? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4537: https://doi.org/10.1002/cca.4537

Sharifan, A. (2025). For adults with multiple sclerosis (MS) and mild to moderate disability, how does virtual reality training compare with no intervention or conventional therapy? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4611: https://doi.org/10.1002/cca.4611

Sharifan, A. (2025). For adults with cancer, what are the benefits and harms of cardiovascular training (either during or after anticancer therapy)? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4604: https://doi.org/10.1002/cca.4604

Sharifan, A. (2025). What are the benefits and harms of classical psychedelics (psilocybin and LSD) for treating anxiety, depression, and existential distress in people with life-threatening diseases? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4512: https://doi.org/10.1002/cca.4512